Clinical Trials · NCT00165399

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Name: Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Dana-Farber Cancer Institute
Enrollment: 62
Start date: Mar 2004
Locations: 5 sites, United States
Primary endpoint: To determine the feasibility of administering chemotherapy and medical castration to men with rising PSA after radical prostatectomy or radiation therapy.

View Gonadorelin compound reference